Valbiotis reports positive Cardio-Liver results; liver product Sept. 23
Valbiotis says its randomized, placebo-controlled Cardio-Liver study of Steadrive was positive and plans to launch ValbiotisPRO Foie in France on Sept. 23.
Valbiotis said its randomized, placebo-controlled Cardio-Liver study of Steadrive produced positive results. The company said it will launch ValbiotisPRO Foie in France on Sept. 23.